Benedetta Fumarola, Liana Signorini, Silvia Lorenzotti, Paola Lanza, Barbara Saccani, Evelyn Van Hauwermeiren, Alice Mulè, Simone Piva, Matteo Rota, Francesco Zuccalà, Francesco Antonio Rasulo, Matteo Filippini, Alberto Bertazzoli, Giovanni Del Fabro, Alberto Matteelli
PURPOSE: COVID-19 associated pulmonary aspergillosis (CAPA) is common and linked with high fatality rates. To assess the impact on the incidence and outcome of CAPA of an antifungal prophylaxis (AFP) we compared two cohorts of COVID-19 patients admitted to intensive care units (ICU) in Brescia, Italy, from January to August 2021. METHODS: The study cohort included all mechanically ventilated patients observed between April 2021 and August 2021 with SARS-CoV-2-pneumonia, who received AFP with oral posaconazole (200 mg every 6 h) and nebulized liposomal amphotericin B (50 mg every 2 weeks) from ICU admission to 7 days after discharge or, if applicable, until tracheostomy removal...
March 26, 2024: Infection